Novo Nordisk's Zenagamtide Shows Promising Diabetes Results

Novo Nordisk has announced impressive results from a phase 2 study of zenagamtide, a new drug for type 2 diabetes. This once-weekly injection led to significant reductions in blood sugar and up to 14.6% weight loss in participants. The study results were so promising that the drug will move on to phase 3 trials. What does it mean for you? If you or someone you know is managing type 2 diabetes, there could be a new treatment option on the horizon that not only helps control blood sugar but also aids in weight loss. Keep an eye out for future updates on this promising development.